Enzolytics (ENZC) Takes a Hit On Broader Market Fall: What Now?

It is often seen that stocks that make significant gains over a short period of time correct quite sharply and that can prove to be a buying opportunity for new investors.

ENZC is a case in point, which has corrected by as much as 60% after it managed to hit a high of $.96 a share in February. In light of that development, it might be a good idea to take a deeper look at the company and its business. Perhaps the most important factor behind the popularity of the Enzolytics stock is the fact that the licensing rights for Pepsin Fraction peptide molecule are owned by the company. It is meant for the treatment of AIDS and it is claimed that the molecule is significantly different from other forms of treatment.

Related:  Vaxart's (VXRT) biggest mistake in losing $17 target

It does not have any toxicity issues and costs considerably less. Last but not the least, the total addressable market for the product as of 2027 could be worth as huge as $37 billion.

Asan Abdiev

CEO and Editor in Chief. Living in the era of dynamic tech change Asan decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring Finance) writing for technology and as well as finance has been one of the precious aspects of his life